FibroGen Amends Financing Agreement for Flexibility

An update from FibroGen ( (FGEN) ) is now available.

On June 5, 2025, FibroGen amended its financing agreement with Morgan Stanley Tactical Value, reducing its required minimum cash balance from $27 million to $22.5 million, potentially enhancing its financial flexibility. Additionally, on June 4, 2025, FibroGen appointed Dr. Michael Kauffman to its Board of Directors, bringing his extensive oncology expertise to the company, while Dr. Aoife Brennan resigned from the board, with no disagreements cited.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

Spark’s Take on FGEN Stock

According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.

FibroGen’s overall stock score is driven by significant financial challenges, including declining revenues and persistent losses, which weigh heavily on its financial health. The technical analysis provides mixed signals, and the valuation remains unattractive due to negative earnings. Although the earnings call presented strategic advancements, the underlying financial issues are substantial concerns that dominate the overall assessment.

To see Spark’s full report on FGEN stock, click here.

More about FibroGen

FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies at the frontiers of cancer biology and anemia. Its product Roxadustat is approved in multiple countries for treating anemia in chronic kidney disease patients. The company is also developing FG-3246, an antibody-drug conjugate for metastatic castration-resistant prostate cancer, and FG-3180, a CD46-targeted PET biomarker.

Average Trading Volume: 948,229

Technical Sentiment Signal: Strong Sell

Current Market Cap: $31.66M

See more insights into FGEN stock on TipRanks’ Stock Analysis page.